D'Souza G, Clemens G, Troy T, et al. - Researchers evaluated assays for detection of human papillomavirus (HPV) DNA [ELISA (DEIA) and Cobas], and RNA (Aptima) in oral rinse samples, and serum HPV oncogene antibodies among cases with HPV-related oropharyngeal cancer (HPV-OPC) and controls. Two hundred ninety-four “at-risk” people (screening) and 133 “high-risk” people [known to previously have oral oncogenic HPV (oncHPV) DNA and/or HPV16 E6/E7 antibodies detected] were examined for biomarker prevalence. Outcomes revealed moderate-to-poor sensitivity of oral rinse HPV testing for HPV-OPC; this suggests that many true positives would be missed in a potential screening scenario. The most promising biomarker evaluated was HPV16 E6 serum antibody.